Preferences in the management of high-risk prostate cancer among urologists in Europe: Results of a web-based survey

BJU International

Volumn 115, Issue 4, 2015, Pages 571-579

  Surcel, Cristian I ^a   Sooriakumaran, Prasanna ^b,c   Briganti, Alberto ^d   De Visschere, Pieter J L ^f   Fütterer, Jurgen J ^g   Ghadjar, Pirus ⁱ   Isbarn, Hendrik ^j   Ost, Piet ^f   Ploussard, Guillaume ^k   Van Den Bergh, Roderick C N ^h   Van Oort, Inge M ^g   Yossepowitch, Ofer ^l,m   Sedelaar, J P Michiel ^g   Giannarini, Gianluca ^e  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e UNIVERSITY OF UDINE   (Italy)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^k ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^l RABIN MEDICAL CENTER   (Israel)

^m TEL AVIV UNIVERSITY   (Israel)

more..

Author keywords

androgen deprivation therapy; high risk prostate cancer; prostatectomy; prostatic neoplasms; radiation therapy; survey

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANDROGEN DEPRIVATION THERAPY; BONE SCINTISCANNING; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; EASTERN EUROPE; EUROPE; EXTERNAL BEAM RADIOTHERAPY; GEOGRAPHY; GLEASON SCORE; HEALTH CARE QUALITY; HIGH RISK PATIENT; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUESTIONNAIRE; RADICAL RETROPUBIC PROSTATECTOMY; REVIEW; SALVAGE THERAPY; UROLOGIST; WESTERN EUROPE; CLINICAL PRACTICE; INFORMATION PROCESSING; INTERNET; MALE; PHYSICIAN; PROSTATIC NEOPLASMS; RADIOTHERAPY; STATISTICS AND NUMERICAL DATA;

ANTINEOPLASTIC AGENTS, HORMONAL; DATA COLLECTION; HUMANS; INTERNET; MALE; NEOPLASM STAGING; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY;

EID: 84925669401     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12796     Document Type: Review

References (30)

1. Yossepowitch O, Eggener SE, Serio AM, et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 2008; 53: 950-959
2. Cooperberg MR, Cowan J, Broering JM, Carroll PR,. High-risk prostate cancer in the United States, 1990-2007. World J Urol 2008; 26: 211-218
3. Walz J, Joniau S, Chun FK, et al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int 2011; 107: 765-770
4. European Association of Urology Guidelines on Prostate Cancer. Latest update available at: http://www.uroweb.org. Accessed March 29, 2014
5. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Prostate Cancer. Version 1. 2014. Latest update available at: http://www.nccn.org. Accessed March 29, 2014
6. Alcaraz A, Burgos FJ, Cõzar JM, et al. Prostate cancer in Spain: from guidelines to clinical practice. BJU Int 2011; 108: 61-66
7. Stensvold A, Dahl AA, Fosså SD, et al. Clinicians' use of guidelines as illustrated by curative treatment of prostate cancer at a comprehensive cancer center. Acta Oncol 2011; 50: 408-414
8. Bauvin E, Soulié M, Ménégoz F, et al. Medical and non-medical determinants of prostate cancer management: a population-based study. Eur J Cancer 2003; 39: 2364-2371
9. Krupski TL, Kwan L, Afifi AA, Litwin MS,. Geographic and socioeconomic variation in the treatment of prostate cancer. J Clin Oncol 2005; 23: 7881-7888
10. Cooperberg MR, Broering JM, Carroll PR,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117-1123
11. ICC/ESOMAR Code on Market and Social Research. Available at: http://www.esomar.org. Accessed March 29, 2014
12. Bastian PJ, Boorjian SA, Bossi A, et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol 2012; 61: 1096-1106
13. Abdollah F, Sun M, Thuret R, et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol 2011; 59: 88-95
14. Kibel AS, Ciezki JP, Klein EA, et al. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol 2012; 187: 1259-1265
15. Nepple KG, Stephenson AJ, Kallogjeri D, et al. Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol 2013; 64: 372-378
16. Sun M, Sammon JD, Becker A, et al. Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. BJU Int 2014; 113: 200-208
17. Lee EK, Baack J, Duchene DA,. Survey of practicing urologists: robotic versus open radical prostatectomy. Can J Urol 2010; 17: 5094-5098
18. Yuh B, Artibani W, Heidenreich A, et al. The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review. Eur Urol 2014; 65: 918-927
19. Tewari AK, Patel ND, Leung RA, et al. Visual cues as a surrogate for tactile feedback during robotic-assisted laparoscopic prostatectomy: posterolateral margin rates in 1340 consecutive patients. BJU Int 2010; 106: 528-536
20. Makarov DV, Yu JB, Desai RA, Penson DF, Gross CP,. The association between diffusion of the surgical robot and radical prostatectomy rates. Med Care 2011; 49: 333-339
21. Briganti A, Blute ML, Eastham JH, et al. Pelvic lymph node dissection in prostate cancer. Eur Urol 2009; 55: 1251-1265
22. Briganti A, Chun FK, Salonia A, et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 2006; 50: 1006-1013
23. Dorin RP, Daneshmand S, Eisenberg MS, et al. Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: a comparative mapping study. Eur Urol 2011; 60: 946-952
24. Davies JD, Simons CM, Ruhotina N, Barocas DA, Clark PE, Morgan TM,. Anatomic basis for lymph node counts as measure of lymph node dissection extent: a cadaveric study. Urology 2013; 81: 358-363
25. Gakis G, Boorjian SA, Briganti A, et al. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur Urol 2013. doi: 10.1016/j.eururo.2013.05.033 [Epub ahead of print]
26. Stephenson AJ, Bolla M, Briganti A, et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 2012; 61: 443-451
27. Suardi N, Gallina A, Lista G, et al. Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy. Eur Urol 2014; 65: 546-551
28. Fleshner N, Rakovitch E, Klotz L,. Differences between urologists in the United States and Canada in the approach to prostate cancer. J Urol 2000; 163: 1461-1466
29. Fayanju OM, Stoll CR, Fowler S, Colditz GA, Jeffe DB, Margenthaler JA,. Geographic and temporal trends in the management of occult primary breast cancer: a systematic review and meta-analysis. Ann Surg Oncol 2013; 20: 3308-3316
30. Kim SP, Gross CP, Nguyen PY, et al. Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer. Prostate Cancer Prostatic Dis 2014; 17: 163-169